Rilotumumab

4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Malignant Esophageal Neoplasm

→ investigated in trials for

2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Esophageal Neoplasm

Observed

→ investigated in trials for

Epithelioid Mesothelioma

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Epithelioid Mesothelioma

Observed

→ investigated in trials for

Fallopian Tube Carcinoma

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Fallopian Tube Carcinoma

Observed

Gastroesophageal Junction Adenocarcinoma

→ investigated in trials for

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Gastroesophageal Junction Adenocarcinoma

Observed

→ investigated in trials for

Glioblastoma

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Glioblastoma

Observed

→ investigated in trials for

Gliosarcomasubtype

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Gliosarcoma

Observed

Lung Small Cell Carcinoma

→ investigated in trials for

Lung Small Cell Carcinomasubtype

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Malignant Colon Neoplasm

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Colon Neoplasm

Observed

Malignant Colorectal Neoplasm

→ investigated in trials for

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Colorectal Neoplasm

Observed

Malignant Digestive System Neoplasm

→ investigated in trials for

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Digestive System Neoplasm

Observed

→ investigated in trials for

Malignant Lung Neoplasm

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Lung Neoplasm

Observed

→ investigated in trials for

Malignant Mesotheliomacancer_family

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Mesothelioma

Observed

→ investigated in trials for

Malignant Neoplasm

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Neoplasm

Observed

Malignant Prostate Neoplasm

→ investigated in trials for

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Prostate Neoplasm

Observed

Malignant Rectal Neoplasm

→ investigated in trials for

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Rectal Neoplasm

Observed

→ investigated in trials for

Ovarian Carcinoma

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Ovarian Carcinoma

Observed

Pleural Solitary Fibrous Tumor

→ investigated in trials for

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Pleural Solitary Fibrous Tumor

Observed

Primary Peritoneal Carcinoma

→ investigated in trials for

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Primary Peritoneal Carcinoma

Observed

→ investigated in trials for

Solid Neoplasm

1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Solid Neoplasm

Observed

Solid Neoplasm,Malignant Lung Neoplasm,Lung Small Cell Carcinoma

Rilotumumab studied in …STUDIED_INderived10 of 13show all (up to 200)
→ studied in	NCT00791154Phase 1/Phase 2 · terminated QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer · 13 trials list this drug (0 active)	—	—	Solid Neoplasm,Malignant Lung Neoplasm,Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00788957Phase 1/Phase 2 · completed Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) · 13 trials list this drug (0 active)	—	—	Malignant Digestive System Neoplasm,Malignant Colorectal Neoplasm,Malignant Colon Neoplasm+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT02154490completed Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer · 13 trials list this drug (0 active)	—	—	Lung Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01443065Phase 2 · completed MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma · 13 trials list this drug (0 active)	—	—	Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02926638Phase 2/Phase 3 · terminated Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches · 13 trials list this drug (0 active)	—	—	Lung Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01039207Phase 2 · completed Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · 13 trials list this drug (0 active)	—	—	Primary Peritoneal Carcinoma,Ovarian Carcinoma,Fallopian Tube Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02137343Phase 3 · terminated A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer · 13 trials list this drug (0 active)	—	—	Malignant Gastric Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01791374Phase 1 · completed Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ · 13 trials list this drug (0 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT01697072Phase 3 · terminated First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma · 13 trials list this drug (0 active)	—	—	Malignant Gastric Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01113398Phase 2 · completed AMG 102 and Avastin for Recurrent Malignant Glioma · 13 trials list this drug (0 active)	—	—	Glioblastoma,Gliosarcoma	1	Observed	clinicaltrials	graph →

Rilotumumab studied in …STUDIED_INderived10 of 13show all (up to 200)

→ studied in

NCT00791154Phase 1/Phase 2 · terminated

QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer · 13 trials list this drug (0 active)

—

Observed

Malignant Digestive System Neoplasm,Malignant Colorectal Neoplasm,Malignant Colon Neoplasm+1

→ studied in

NCT00788957Phase 1/Phase 2 · completed

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) · 13 trials list this drug (0 active)

—

Observed

→ studied in

NCT02154490completed

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer · 13 trials list this drug (0 active)

—

Observed

Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm

→ studied in

NCT01443065Phase 2 · completed

MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma · 13 trials list this drug (0 active)

—

Observed

→ studied in

NCT02926638Phase 2/Phase 3 · terminated

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches · 13 trials list this drug (0 active)

—

Observed

Primary Peritoneal Carcinoma,Ovarian Carcinoma,Fallopian Tube Carcinoma

→ studied in

NCT01039207Phase 2 · completed

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · 13 trials list this drug (0 active)

—

Observed

→ studied in

NCT02137343Phase 3 · terminated

A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer · 13 trials list this drug (0 active)

—

Observed

→ studied in

NCT01791374Phase 1 · completed

Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ · 13 trials list this drug (0 active)

—

not mapped

Observed

→ studied in

NCT01697072Phase 3 · terminated

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma · 13 trials list this drug (0 active)

—

Observed

→ studied in

NCT01113398Phase 2 · completed

AMG 102 and Avastin for Recurrent Malignant Glioma · 13 trials list this drug (0 active)

—

Glioblastoma,Gliosarcoma

Observed